Founded in 2018, Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis
Oslo, Oslo
Founded in 2018
1-10 employees
Founded in 2018, Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis
Company Information
- Industry
- Company Type
- Privately Held
- Founded
- 2018
- Employee Range
- 1-10
- Revenue Range
- Not available
Location
- Address
- City
- Oslo
- Region
- Oslo
- Postal Code
- Country
- Norway
Web Presence
Websitearxxtx.com
LinkedIn0 followers